Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | FURIN | P09958 | 2/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | TFPI | P10646 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567745 | 0.90 | BACE1 (0.47) | NPBWR1BACE1 | |
| SCHEMBL23154857 | 0.90 | FURIN (0.47) | OPRM1OPRD1NPBWR1OPRK1FURIN | |
| SCHEMBL23639488 | 0.90 | FURIN (0.47) | OPRM1OPRD1NPBWR1OPRK1FURIN | |
| SCHEMBL28831855 | 0.90 | OPRL1 (0.49) | OPRM1OPRD1OPRK1OPRL1TFPI | |
| SCHEMBL29461378 | 0.89 | BACE1 (0.50) | OPRM1OPRD1NPBWR1FURINOPRL1 | |
| SCHEMBL30930140 | 0.89 | GLP1R (0.49) | OPRL1TFPIBACE1 | |
| SCHEMBL30930145 | 0.88 | GLP1R (0.48) | OPRL1TFPIBACE1 | |
| SCHEMBL30997405 | 0.88 | GLP1R (0.48) | OPRL1TFPIBACE1 | |
| SCHEMBL30262131 | 0.87 | TFPI (0.51) | OPRL1TFPIBACE1 | |
| SCHEMBL30903288 | 0.87 | BACE1 (0.48) | OPRM1OPRD1NPBWR1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117327151-A | Royal jelly wound healing promoting polypeptide AMLK11 and application thereof | 福建农林大学 | 2024-01-02 | — | — | CN | disclosed |